In the absence of a definitive trial comparing these regimens and to inform therapeutic decisions, Daud et al. performed an indirect treatment comparison of the dabrafenib/trametinib and vemurafenib/cobimetinib regimens from randomized phase III trials of patients with BRAF-mutant melanoma [26]. This evidence concerns the gene BRAF and melanoma.